GlassScriptPhysician profile
Daisy Acevedo Morales
NPI 1891938429
$12,790.49
in general payments reported to CMS, 2019-2025
53 companies · $4,302 in 2025
The $4,302 reported for 2025 was more than what 86% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $318 · 2021: $929 · 2022: $584 · 2023: $2,215 · 2024: $3,947 · 2025: $4,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,464.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,742.45 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,326.85 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $757.19 | 2020-2025 | Evenity, Tepezza, Prolia |
| Mannkind Corporation | $574.78 | 2019-2025 | Afrezza |
| Xeris Pharmaceuticals, INC. | $574.67 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Bayer Healthcare Pharmaceuticals INC. | $560.64 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $552.68 | 2019-2025 | |
| Tandem Diabetes Care, INC. | $473.88 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $472.75 | 2023-2025 | Isturisa, Signifor Lar |
| Insulet Corporation | $452.19 | 2020-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $446.32 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Dexcom, INC. | $385.67 | 2023-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Radius Health, INC. | $363.41 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $311.37 | 2021-2023 | |
| Abbott Laboratories | $293.01 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $292.11 | 2019-2021 | |
| Corcept Therapeutics | $267.02 | 2021-2025 | Korlym |
| Abbvie INC. | $231.82 | 2021-2025 | Synthroid |
| Pfizer INC. | $214.11 | 2019-2025 | |
| Beta Bionics, INC. | $195.84 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Cequr Corporation | $179.34 | 2022-2025 | Cequr Simplicity |
| Alvogen INC | $168.33 | 2023-2025 | Teriparatide |
| Amneal Pharmaceuticals LLC | $158.61 | 2021-2024 | Unithroid |
| Ibsa Pharma INC. | $149.65 | 2023-2025 | Tirosint, Licart, Flector |
| Ascendis Pharma Endocrinology INC | $146.49 | 2025 | Yorvipath, Skytrofa |
| Antares Pharma, INC. | $143.95 | 2024-2025 | Xyosted |
| Sequel Med Tech, LLC | $137.75 | 2025 | Twiist |
| Shire North American Group INC | $119.37 | 2019 | |
| Verity Pharmaceuticals INC. | $109.04 | 2024-2025 | Tlando |
| Medtronic Minimed, INC. | $108.88 | 2019 | |
| Embecta Corp. | $84.87 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Neurocrine Biosciences, INC. | $78.38 | 2025 | |
| Kyowa Kirin, INC. | $74.43 | 2023-2025 | Crysvita |
| Halozyme INC | $67.11 | 2023 | |
| Glaxosmithkline, LLC. | $56.97 | 2025 | Shingrix, Arexvy |
| Alexion Pharmaceuticals, INC. | $53.07 | 2025 | Strensiq |
| Soleno Therapeutics, INC. | $49.96 | 2025 | Vykat Xr |
| Rhythm Pharmaceuticals, INC. | $43.80 | 2025 | Imcivree |
| Hologic Sales and Service, LLC | $42.78 | 2023-2025 | Thinprep 2000 Processor, Aptima |
| Medtronic, INC. | $37.85 | 2023-2024 | Minimed 780g, Mycarelink |
| Vivus LLC | $37.73 | 2023-2024 | Qsymia, Pancreaze |
| Acella Pharmaceuticals, LLC | $34.32 | 2024-2025 | NP Thyroid 60 |
| Ionis Pharmaceuticals, INC. | $33.50 | 2025 | Tryngolza |
| Amphastar Pharmaceuticals, INC. | $24.96 | 2025 | |
| Chiesi USA, INC. | $21.76 | 2024 | Mycapssa |
| Aimmune Therapeutics, INC. | $19.99 | 2025 | Zenpep |
| Evoke Pharma, INC. | $19.26 | 2025 | |
| Ascensia Diabetes Care US INC. | $18.93 | 2025 | |
| Horizon Therapeutics Plc | $18.08 | 2023 | Tepezza |
| Astellas Pharma US INC | $17.78 | 2024 | Veozah |
| Nevro Corp. | $17.26 | 2022 | |
| Boston Scientific Corporation | $13.77 | 2021 | |
| Tolmar, INC. | $13.76 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daisy Acevedo Morales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.